ASX:TDL

Stock Analysis Report

Executive Summary

TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, assays, instruments, and services in the United States, Taiwan, and China.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has TBG Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TDL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

18.2%

TDL

-2.4%

AU Biotechs

-2.2%

AU Market


1 Year Return

-36.6%

TDL

72.6%

AU Biotechs

11.6%

AU Market

Return vs Industry: TDL underperformed the Australian Biotechs industry which returned 72.6% over the past year.

Return vs Market: TDL underperformed the Australian Market which returned 11.6% over the past year.


Shareholder returns

TDLIndustryMarket
7 Day18.2%-2.4%-2.2%
30 Day-18.8%4.1%-2.2%
90 Day-42.2%15.7%2.2%
1 Year-36.6%-36.6%74.7%72.6%16.5%11.6%
3 Year-84.7%-84.7%181.1%171.0%36.2%18.1%
5 Yearn/a257.2%233.8%46.7%14.1%

Price Volatility Vs. Market

How volatile is TBG Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TBG Diagnostics undervalued compared to its fair value and its price relative to the market?

0.25x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TDL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TDL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TDL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: TDL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TDL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TDL is good value based on its PB Ratio (0.3x) compared to the AU Biotechs industry average (3.3x).


Next Steps

Future Growth

How is TBG Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TBG Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has TBG Diagnostics performed over the past 5 years?

0.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TDL is currently unprofitable.

Growing Profit Margin: TDL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TDL is unprofitable, but has reduced losses over the past 5 years at a rate of 0.1% per year.

Accelerating Growth: Unable to compare TDL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TDL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.2%).


Return on Equity

High ROE: TDL has a negative Return on Equity (-10.63%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is TBG Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: TDL's short term assets (A$8.8M) exceed its short term liabilities (A$1.2M).

Long Term Liabilities: TDL's short term assets (A$8.8M) exceed its long term liabilities (A$88.5K).


Debt to Equity History and Analysis

Debt Level: TDL's debt to equity ratio (1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if TDL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: TDL has a low level of unsold assets or inventory.

Debt Coverage by Assets: TDL's debt is covered by short term assets (assets are 38.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TDL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: TDL has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of -5.5% each year.


Next Steps

Dividend

What is TBG Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.5%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate TDL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TDL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TDL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TDL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TDL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

TBG Diagnostics has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Indrajit Arulampalam
Executive Chairman0yrsAU$80.00k0.018% A$1.0k
Generosa Hipona
Chief Financial Officer0yrsAU$140.48kno data
Justyn Stedwell
Company Secretary3.2yrsAU$36.00kno data
Willy Hsu
Chief Operating Officer1yrsno datano data
Michael Chen
Chief Scientific Officer14.1yrsno datano data
Edward Hammond
Head of Biology0yrsno datano data
Paul Handley
Head of Chemistry0yrsno datano data
Tomislav Karoli
Head of Process Chemistry0yrsno datano data
Ifan Chiu
President of TBG (Xiamen) Inc0yrsno data0.30% A$17.1k

3.2yrs

Average Tenure

Experienced Management: TDL's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Indrajit Arulampalam
Executive Chairman0yrsAU$80.00k0.018% A$1.0k
Shi-Chung Chang
Non-Executive Director4.2yrsAU$40.00k0.23% A$13.0k
Emily Lee
Non-Executive Director4.2yrsAU$40.00k0.042% A$2.4k
His-Kai Wang
Director1.8yrsAU$23.33kno data

4.2yrs

Average Tenure

Experienced Board: TDL's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

TBG Diagnostics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TBG Diagnostics Limited
  • Ticker: TDL
  • Exchange: ASX
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$5.657m
  • Shares outstanding: 217.59m
  • Website: https://www.tbgbio.com

Location

  • TBG Diagnostics Limited
  • 138 Juliette Street
  • Unit 6
  • Greenslopes
  • Queensland
  • 4120
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TDLA.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 2004
TDLASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 2004
PG1DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2004
TDLASX (Australian Securities Exchange)NPVAUAUDFeb 2016

Biography

TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, assays, instruments, and services in the United States, Taiwan, and China. The company offers nucleic acid extraction, human leukocyte antigen (HLA) sequence specific primer typing, HLA sequence based typing, and HPA genotyping kits, as well as reagents and accessories; halotype HLA NGS products; equipment comprising nucleic acid extraction, automated pipetting, and gel electrophoresis systems; and HLA genotyping and contract manufacturing services, as well as reagents analysis software. It serves clinical labs of hospitals and independent reference labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. The company was incorporated in 1989 and is based in Greenslopes, Australia. TBG Diagnostics Limited is a subsidiary of Medigen Biotechnology Corporation. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 10:31
End of Day Share Price2020/02/25 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.